U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06885281) titled 'A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants with Selected Solid Tumors' on Feb. 24.

Brief Summary: A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: GEP-NEC LCNEC NEPC Other NECs or DLL3-expressing Solid Tumors (other Than NEC)

Intervention: DRUG: ZL-1310

2.0 mg/kg Q3W ZL-1310

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Disclaimer: Curated by HT Syndication....